Clinical presentation and monitoring of lupus nephritis

Lupus

Volumn 14, Issue 1, 2005, Pages 25-30

  Balow, J E ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Lupus nephritis; Lupus serologies; Renal function; Urine sediment

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1Q ANTIBODY; DNA ANTIBODY; NUCLEOSOME ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY TITER; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL RESEARCH; COMPLEMENT CLASSICAL PATHWAY; DISEASE ACTIVITY; GLOMERULONEPHRITIS; HEMATURIA; KIDNEY DISEASE; KIDNEY FUNCTION TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; NEPHRITIS; NEPHROTIC SYNDROME; PATIENT MONITORING; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

HUMANS; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; PROTEINURIA; RECURRENCE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; URINALYSIS;

EID: 13444257507     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203305lu2055oa     Document Type: Review

References (22)

1. Houssiau FA. Management of lupus nephritis: an update. J Am Soc Nephrol 2004; 15: 2694-2704.
2. Balow JE, Boumpas DT, Austin HA III. Lupus Nephritis. In Brady HR, Wilcox CS eds. Therapy in Nephrology and Hypertension. 2nd edition. London: WB Saunders, 2003: 153-164.
3. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277. Updated criteria: Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
4. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-1277. Updated criteria: Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
5. Balow JE, Boumpas DT, Austin HA III. Systemic lupus erythematosus and the kidney. In Lahita RG ed. Systemic Lupus Erythematosus. 4th edition. Elsevier: Amsterdam, 2004; 877-912.
6. Lewis EJ, Schwartz MM, Korbet SM eds. Lupus nephritis. Oxford: Oxford University Press, 1999: 1-315.
7. Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
8. Fogazzi GB, Ponticelli C, Ritz E. The Urinary Sediment, 2nd edition. Oxford: Oxford University Press, 1999; 1-188.
9. Rasoulpour M, Banco L, Laut JM, Burke GS. Inability of community-based laboratories to identify pathological cast in urine samples. Arch Pediatr Adolesc Med 1996; 150: 1201-1204.
10. Chitalia VC, Kothari J, Wells EJ et al. Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio. Clin Nephrol 2001; 55: 436-447.
11. Christopher-Stine L, Petri M, Astor BC, Fine D. Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. J Rheumatol 2004; 31: 1557-1559.
12. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
13. Korbet SM, Lewis EJ, Schwartz MM et al. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000; 35: 904-914.
14. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy. Arthritis Rheum 2002; 46: 995-1002.
15. Hahn BH. Antibodies to DNA. N Engl J Med 1998; 338: 1359-1368.
16. Berden JH. Lupus nephritis (Nephrology Forum). Kidney Int 1997; 52: 538-558.
17. Trouw LA, Groeneveld TW, Seelen MA et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune deposits. J Clin Invest 2004; 114: 679-688.
18. Marto N, Bertolaccini ML, Calabuig E et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis; published ahead online 29 July 2004 at http://wd.bmjjournals.com/cgi/reprint/and.2004.0249453v1
19. Manzi S, Ahearn JM, Salmon J. New insights into complement: a mediator of injury and marker of disease activity in systemic lupus erythematosus. Lupus 2004; 13: 298-303.
20. Bootsma H, Spronk P, Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-1599.
21. Urowitz MB, Gladman DD. Clinical monitoring. In The clinical management of systemic lupus erythematosus, 2nd edition. Schur PH ed. Lippincott-Raven: Philadelphia, 1996: 225-233.
22. Strand V, Gladman D, Isenberg D et al. Endpoints: consensus recommendations from OMERACT IV. Outcome measures in rheumatology. Lupus 2000; 9: 322-327.